AstraZeneca plans to move all production of the vital molecules in its medicines offshore, mainly to China.

The pharmaceuticals company’s cost-cutting drive, which will continue for some years, means that it will cease to produce or source active pharmaceutical ingredients (API) in the UK Story continues here ➤